SignalXSignalX

Becton Dickinson (BDX) Q4 2025 10-Q Quarterly Report

Filed: Feb 9, 2026Period ending Dec 31, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR
Becton Dickinson Overview

Becton Dickinson (BDX) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 9, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

Becton Dickinson Q4 2025 10-Q Analysis

Management Discussion & Analysis

  • • Revenue $5.252B, up 1.6% YoY from $5.168B, driven by 1.2% FX impact; U.S. revenue growth 2.6%, international revenue flat (+0.2%)
  • • Gross profit margin 45.9% vs 43.3% YoY; operating performance margin declined 1.3%; selling/admin expense 26.5% vs 25.5%; R&D expense 5.8% vs 6.6%
  • • Best segment: Interventional revenue $1.330B up 5.8%, segment margin 42.1% vs 44.6%; Worst segment: Life Sciences revenue down 8.3%, segment margin 20.8% vs 28.7%
  • • Operating cash flow $657M; cash/short-term investments $1.035B; repurchased $250M stock, paid $299M dividends; $2B planned for share repurchase next quarter
  • • Near-term headwinds: Tariffs increasing costs, VoBP in China reducing volumes, FDA regulatory uncertainties for Infusion Systems, ethylene oxide sterilization regulations

Risk Factors

  • • No material changes to risk factors from 2025 Annual Report
  • • Product liability and regulatory compliance risks from healthcare regulations remain significant
  • • Competitive pressures from new entrants and technology innovation continue to impact market share
  • • Supply chain disruptions and operational risks persist amid global uncertainty
  • • Currency fluctuations and debt service obligations continue to pose financial risks

Becton Dickinson Q4 2025 Quarterly Financials
XBRL

Revenue

$5.3B

▲ +1.6% YoY

Net Income

$382M

▲ +26.1% YoY

Operating Margin

10.5%

▲ +174bp YoY

Net Margin

7.3%

▲ +141bp YoY

ROE

1.5%

▲ +31bp YoY

Total Assets

$54.8B

▲ +0.3% YoY

EPS (Diluted)

$1.34

▲ +28.8% YoY

Operating Cash Flow

$657M

▼ -5.2% YoY

Source: XBRL data from Becton Dickinson Q4 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Becton Dickinson Quarterly Reports

Q2 2025 10-Q
Q1 2025 10-Q

Get deeper insights on Becton Dickinson

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.